- $179.94m
- $57.76m
- $7.67m
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate
Brief: Adagene Inc - Partners With Conjugatebio For Antibody Drug Conjugate Development
Brief: Adagene Announces Up To $25 Million Strategic Investment From Sanofi
Brief: Adagene Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: Adagene Announces Upcoming Poster Presentations On ADG126 At Society For Immunotherapy Of Cancer Annual Meeting
Brief: Adagene Says Cash Balance Of about Us$110 Million Funds Streamlined Operations Into 2026
Brief: Adagene Presents Interim Results Of Masked Anti-CTLA-4 SAFEbody ADG126 in Combination with Pembrolizumab in Metastatic Microsatellite-stable Colorectal Cancer
Brief: Adagene Inc - Cash Balance Of $128.8 Million Supports Operations To Late 2025
Brief: Adagene Achieves $3 Million Milestone In Collaboration With Exelixis
Brief: Adagene Presents Clinical Data For Anti-Ctla-4 Safebody®
Brief: Adagene Reports Full Year 2022 Financial Results And Provides Corporate Update
Adagene rises on collaboration with Roche for liver cancer drug
Brief: Adagene Announces Clinical Trial Collaboration To Evaluate Anti-Ctla-4 Safebody® Adg126 In Combination With Roche’S Standard-Of-Care For First-Line Advanced Liver Cancer
Brief: Adagene Announces Clinical Data At Sitc 2022 On Anti-Ctla-4 Neobody, Adg116
Brief: Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming SITC Annual Meeting In November
Adagene shares rise on buyback program